MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Myriad reported its Q2 2026 financial results on July 30, 2026. The Company’s revenue fell 11% year-over-year, while it also cut its full-year revenue guidance, lowered gross margin expectations, and suspended its EBITDA guidance. Based on this news, shares of Myriad fell sharply.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at david@schallfirm.com